• Biomolecules & Therapeutics
• /
• 제6권4호
• /
• pp.412-416
• /
• 1998

Acute oral toxicity of Bifidobacterium breve K-110, Bifidobacterium breve K-111, Bifidobacterium infantis K-525 were studied in Sprague-Dawley rats of both sexes. In this study, we examined number of deaths, clinical signs, bod weight and gross findings for 14 day after single oral administration of B. breve K-110,B. breve K-111 or B. infantis K-525 with different levels. They did not show any toxic effect in rats and oral LD$_{50}$ value was over 5 g/kg in rats.s.

• 한국식품과학회지
• /
• 제31권2호
• /
• pp.547-552
• /
• 1999

저자 등이 건강한 한국사람으로부터 장내유해효소를 억제할 수 있은 장내환경개선효과가 우수한 한국형 유산균을 분리하여 소장수송능 효과, castor oil을 이용한 설사모델 동물에서 지사효과 및 항돌연변이 효과를 측정한 결과 소장의 수송능에는 아무런 영향을 미치지 못했으나 대장의 소송능은 현저한 수송능 촉진효과를 나타냈으며 특히 Bifidobacterium breve K-110의 균주가 우수하였다. Castor oil로 유도된 설사에 대한 지사 효과는 대부분의 균주에서 억제효과가 인정되지 않았으나, K-111의 균주는 유의한 지사효과를 나타냈다. 아울러 유산균은 항돌연변이 효과는 Bifidobacterium breve K-100 균주가 가장 우수한 효과를 나타내었으며 이러한 효과는 유산균의 세포벽 성분이 peptidoglycan에 의한 효과였다. 이러한 결과들로 볼 때 한국형유산균은 장내세균이 생산하는 유해효소의 생산성을 억제하는 것외에도 설사와 변비를 개선할 수 있으며 발암물질에 의한 항돌연변이 효과을 통해서 장내환경개선 효과를 기대할 수 있을 것으로 생각된다.

• 약학회지
• /
• 제42권6호
• /
• pp.639-641
• /
• 1998

Minimal inhibitory concentrations (MICs) of Bifidobacterium spp. strains (Bifidobacterium breve K-110, B. breve K-111 and B. infantis K-525) isolated from healthy Korean against antituberculosis agents and fluoroquinolones were determined. From the MICs it was found that Bifidobacterium breve K-110, B. breve K-111 and B. infantis K-525 were susceptible to rifampicin and fluoroquinolenes and resistant to other antituberculosis agents.

• Journal of Microbiology and Biotechnology
• /
• 제5권5호
• /
• pp.285-291
• /
• 1995

Saccharide utilizations for the growth by Bifidobacterium longum and Bifidobacterium breve were compared. B. longum fermented glucose more rapidly than lactose as a carbon source whereas B. breve fermented lactose at a rate higher than that of glucose. The highest cell concentration, in the case of B. longum, was obtained when cultivated in a jar fermentor that contained modified MRS medium that half the beef extract was replaced by the same amount of tuna extract, and that pH was controlled at 6.0. B. breve showed the best growth when grown in a jar fermentor containing the MRS medium with lactose instead of glucose, controlled at pH 6.0. The optimal concentration of peptone in MRS medium for the growth of B. breve was 5 g/l.

• 한국식품위생안전성학회지
• /
• 제37권5호
• /
• pp.306-309
• /
• 2022

프로바이오틱스가 널리 사용됨에 따라 European Food Safety Authority (EFSA)와 식품의약품안전평가원이 제시하는 프로바이오틱스 안전성 평가 가이드라인에 준수하여 B. breve BB077의 안전성을 평가하였다. 본 실험에 사용한 B. breve BB077 균주는 용혈성이 발생하지 않았으며, 독소를 거의 생성하지 않았음을 확인하였다. 항생제 내성 평가에서는 7종의 항생제에서는 EFSA 권고 cut-off value 보다 낮은 항생제 내성을 보였으며, 2종의 항생제인 streptomycin와 tetracycline에서는 cut-off value 보다 높은 항생제 내성을 보였다. streptomycin, tetracycline에 대한 내성 결정인자는 B. breve 종의 공통 유전적 특징으로 외부로부터 전달 받은 내성이 아닌 자연돌연변이에 의한 획득내성이기에 사용에 안전한 균주임을 확인하였다.

• Journal of Microbiology and Biotechnology
• /
• 제31권7호
• /
• pp.949-955
• /
• 2021

Previously, our research group isolated Bifidobacterium breve IDCC4401 from infant feces as a potential probiotic. For this study, we evaluated the safety of B. breve IDCC4401 using genomic and phenotypic analyses. Whole genome sequencing was performed to identify genomic characteristics and investigate the potential presence of genes encoding virulence, antibiotic resistance, and mobile genetic elements. Phenotypic analyses including antibiotic susceptibility, enzyme activity, production of biogenic amines (BAs), and proportion of D-/L-lactate were evaluated using E-test, API ZYM test, high-performance liquid chromatography (HPLC), and D-/L-lactic acid assay respectively. The genome of B. breve IDCC4401 consists of 2,426,499 bp with a GC content of 58.70% and 2,016 coding regions. Confirmation of the genome as B. breve was provided by its 98.93% similarity with B. breve DSM20213. Furthermore, B. breve IDCC4401 genes encoding virulence and antibiotic resistance were not identified. Although B. breve IDCC4401 showed antibiotic resistance against vancomycin, we confirmed that this was an intrinsic feature since the antibiotic resistance gene was not present. B. breve IDCC4401 showed leucine arylamidase, cystine arylamidase, α-galactosidase, β-galactosidase, and α-glucosidase activities, whereas it did not show production of harmful enzymes such as β-glucosidase and β-glucuronidase. In addition, B. breve IDCC4401 did not produce any tyramine, histamine, putrescine, cadaverine, or 2-phenethylamine, which are frequently detected BAs during fermentation. B. breve IDCC4401 produced 95.08% of L-lactate and 4.92% of D-lactate. Therefore, our findings demonstrate the safety of B. breve IDCC 4401 as a potential probiotic for use in the food industry.

• Journal of Microbiology and Biotechnology
• /
• 제9권3호
• /
• pp.368-370
• /
• 1999

The protective role of Bifidobacterium spp. (B. breve K-110, B. breve K-111, and B. infantis K-525) isolated from the fecal samples of healthy Koreans was investigated on 1,2-dimethylhydrazine (DMH)-induced aberrant crypt foci(ACF) formation in mouse colon. In mice fed normal diet with DMH treatment, an average of 68.5 ACF/colon was formed, whereas in mice administered with B. breve K-110, B. breve K-111, and B. infantis K-525, the numbers of DMH-induced ACF decreased to 7.2, 10.9, and 6.6 ACF/ colon, respectively. The mean number of crypts/focus was not significantly altered. Fecal harmful enzymes, such as β-glucuronidase, tryptophanase, and urease, were effectively inhibited during the administration of these bifidobacteria to mice. These results suggest that bifidobacteria could prevent colon cancer.

• 한국식품과학회지
• /
• 제31권4호
• /
• pp.1096-1100
• /
• 1999

The protective effect of Bifidobacterium breve K-110, K-111 and B. infantis K-525 on carbon tetrachloride induced hepatotoxicity in rats was investigated. Among them, B. infantis K-525 had the most potent hepatoprotective activity. It reduced serum aspartate aminotransferase and alanine aminotransferase levels to 51% and 80% of the $CCl_{4}-treated$ groups, respectively. In rat liver homogenate intoxificated with $CCl_{4}$, B. infantis K-525 inhibited in vitro as well as in vivo lipid peroxidation more than the other Bifidobacteria.

• 한국미생물·생명공학회지
• /
• 제49권1호
• /
• pp.1-8
• /
• 2021

Human breast milk is a potential source of bacteria for the development of the intestinal microbiota of infants. Several species within the genera Lactobacillus and Bifidobacterium were demonstrated to shape the gut microbiota of infants. In this study, the bacterial diversity was investigated in the breast milk and feces of a mother-infant pair, and probiotic candidates were identified. Importantly, the novel L. gasseri EJL and B. breve JTL strains were isolated from breast milk and infant feces samples, respectively; their completed genome was resolved using de novo sequencing. In addition, the bacterial composition in the infant's feces at 1 week revealed the prevalence of Bifidobacterium and Streptococcus; a higher diversity was observed after 3 weeks. In particular, the abundance of Akkermansia was sharply increased at 7 weeks, further increasing thereafter, up to 15 weeks. Our results suggest that human breast milk and infant's feces are a source of probiotic candidates.

• 한국축산식품학회지
• /
• 제38권4호
• /
• pp.806-815
• /
• 2018

This study was performed to isolate some strains of Bifidobacterium breve from fecal materials of neonates and to screen them for the biotransformation activity of converting linoleic acid into conjugated linoleic acid (CLA). Fecal samples were collected from twenty healthy neonates between 14 and 100 days old, and four hundred colonies were randomly selected from a Bifidobacterium selective transoligosaccharide medium. A duplex polymerase chain reaction technique was developed for the rapid and accurate molecular characterization of the B. breve strains that have been reported to show the species-specific characteristic of CLA production. They are identified by 16S ribosomal DNA, fructose-6-phosphate phosphoketolase encoding genes (xfp), and rapid pulsed field gel electrophoresis. Thirty-six isolates were identified as B. breve, and just two of the 12 neonates were harboring B. breve strains. Each isolate showed different CLA-producing ability in the spectrophotometric assay. All of the positive strains from the primary spectrophotometric assay were confirmed for their CLA-producing activities using gas-chromatographic analysis, and their conversion rates were different, depending on the strain isolated in this study. Some strains of B. breve were successfully isolated and characterized based on the CLA-producing activity, and further studies are necessary to characterize the enzyme and the gene responsible for the enzyme activity.